<DOC>
	<DOCNO>NCT02180295</DOCNO>
	<brief_summary>The study evaluate consistency 3 lot inactivate VZV vaccine safety , tolerability , immunogenicity healthy adult . The primary hypothesis study 3 lot inactivated vaccine demonstrate similar immunogenicity 28 day fourth dose .</brief_summary>
	<brief_title>A Lot-to-Lot Consistency Study Evaluate Safety , Tolerability , Immunogenicity Inactivated Varicella Zoster Virus ( VZV ) Vaccine Healthy Adults ( V212-014 )</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Afebrile ( &lt; =100.4 °F [ &lt; =38.0 °C ] ) oral equivalent Day 1 first vaccination Any underlying chronic illness stable condition History varicella , antibody VZV , residence ( &gt; =30 year ) country endemic VZV infection Female participant childbearing potential must negative pregnancy test . A female reproductive potential reach natural menopause , 6weeks postsurgical bilateral oophorectomy and/or hysterectomy bilateral tubal ligation Male , female childbearing potential agrees remain abstinent use 2 acceptable method birth control 2 week enrollment 6 month last study vaccination History allergic reaction vaccine component , anaphylactic/anaphylactoid reaction neomycin ( include contact dermatitis neomycin ) Prior history herpes zoster History receipt expect receive varicella zoster vaccine study period Is pregnant breastfeeding , expect conceive 2 week enrollment 6 month last study vaccination Has receive live virus vaccine schedule receive live virus vaccine 4 week first dose study vaccination throughout study Has receive inactivate vaccine schedule receive inactivate vaccine 7 day 7 day study vaccination Received immunoglobulin blood product schedule receive 5 month first dose study vaccination throughout study Has participate investigational drug vaccine study within 30 day enrollment Has acute illness significant underlying illness may interfere interpretation study Receiving immunosuppressive therapy ( include systemic corticosteroid dos exceed physiological replacement dos within 14 day prior first vaccination ) , except topical , ophthalmic , inhaled corticosteroid intraarticular softtissue injection steroid Has know suspect immune dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>